cx-01
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02873338)
Timeline
Indications
Mechanism of action
PRPF4 inhibitor
- Stromal cell-derived factor 1INHIBITOR
CXCL12 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cx-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02995655 | Phase 1 | Apr 7, 2017 | Cantex Pharmaceuticals, Washington University in St. Louis |
| NCT02873338 | Phase 2 | Aug 1, 2016 | Cantex Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cantex Pharmaceuticals | For profit | 2 | 1 | 2 | 2016 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1